Novo Nordisk's Wegovy shows promise in cutting cardiovascular risk but faces supply shortages and insurance coverage challenges

Clinical trial shows Wegovy reduces risk of heart attack and stroke by 20% compared to placebo.
High demand and limited manufacturing capacity have led Novo Nordisk to restrict supplies of Wegovy.
Insurers have been reluctant to cover Wegovy for non-diabetic patients due to lack of evidence for health benefits.
Novo Nordisk hopes trial data will persuade payers like Medicare to reimburse costs of around $1300 per month.
Further analysis of trial data may reveal additional health benefits beyond weight loss and heart disease risk reduction.